Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical review on triglycerides
Ulrich Laufs, Klaus G. Parhofer, Henry N. Ginsberg, et al.
European Heart Journal (2019) Vol. 41, Iss. 1, pp. 99-109c
Open Access | Times Cited: 418

Showing 26-50 of 418 citing articles:

Triglycerides and risk of atherosclerotic cardiovascular disease: An update
Michel Farnier, Marianne Zeller, David Masson, et al.
Archives of cardiovascular diseases (2021) Vol. 114, Iss. 2, pp. 132-139
Open Access | Times Cited: 71
Remnant lipoproteins: are they equal to or more atherogenic than LDL?
Carlos A. Aguilar‐Salinas, M. John Chapman
Current Opinion in Lipidology (2020) Vol. 31, Iss. 3, pp. 132-139
Open Access | Times Cited: 70
The Effect of Dietary Interventions on Hypertriglyceridemia: From Public Health to Molecular Nutrition Evidence
Karla Paulina Luna-Castillo, Xochitl Citlalli Olivares-Ochoa, Rocío Guadalupe Hernández-Ruiz, et al.
Nutrients (2022) Vol. 14, Iss. 5, pp. 1104-1104
Open Access | Times Cited: 41
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid
M. John Chapman, José Luís Zamorano, Klaus G. Parhofer
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108172-108172
Open Access | Times Cited: 40
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Daniel Gaudet, Peter Clifton, David Sullivan, et al.
NEJM Evidence (2023) Vol. 2, Iss. 12
Closed Access | Times Cited: 32
Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors
Michaël Domanski, Colin O. Wu, Xin Tian, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 12, pp. 1151-1161
Closed Access | Times Cited: 28
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Alejandro Gugliucci
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4399-4399
Open Access | Times Cited: 28
Triglyceride-Glucose Index As A Biomarker Of Insulin Resistance, Diabetes Mellitus, Metabolic Syndrome, And Cardiovascular Disease: A Review.
Liong Boy Kurniawan
PubMed (2024) Vol. 35, Iss. 1, pp. 44-51
Closed Access | Times Cited: 14
The chylomicron saga: time to focus on postprandial metabolism
Alejandro Gugliucci
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 12
Trends in epidemiology of dyslipidemias in India
Sonali Sharma, Kiran Gaur, Rajeev Gupta
Indian Heart Journal (2024) Vol. 76, pp. S20-S28
Open Access | Times Cited: 11
Normal triglyceride concentration and the risk of diabetes mellitus type 2 in the general population of China
Rubing Guo, Lianhua Wei, Yongtong Cao, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Understanding Hypertriglyceridemia: Integrating Genetic Insights
Mara Alves, Francisco Laranjeira, Georgina Correia‐da‐Silva
Genes (2024) Vol. 15, Iss. 2, pp. 190-190
Open Access | Times Cited: 8
New approaches to triglyceride reduction: Is there any hope left?
Annalisa Filtz, Siddhant Parihar, G Greenberg, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100648-100648
Open Access | Times Cited: 8
Triglyceride-rich lipoproteins and cardiovascular diseases
Dandan Xu, Lin Xie, Cheng Cheng, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 8
Longitudinal changes in remnant cholesterol and the risk of cardiovascular disease
Yijun Zhang, Qin Xu, Xue Tian, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine
Julia Kenkre, Tina Mazaheri, R. Dermot G. Neely, et al.
Annals of Clinical Biochemistry International Journal of Laboratory Medicine (2025)
Closed Access | Times Cited: 1
Triglyceride levels and its association with all-cause mortality and cardiovascular outcomes among patients with heart failure
Qing-Wen Ren, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Julius L. Katzmann, Chris J. Packard, M. John Chapman, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 5, pp. 563-579
Open Access | Times Cited: 68
Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Michel R. Langlois, Allan D. Sniderman
Current Cardiology Reports (2020) Vol. 22, Iss. 8
Closed Access | Times Cited: 52
Smartphone-based colorimetric sensor application for measuring biochemical material concentration
Taif Alawsi, Gabriele Proietti Mattia, Zainab Al-Bawi, et al.
Sensing and Bio-Sensing Research (2021) Vol. 32, pp. 100404-100404
Open Access | Times Cited: 50
Brown adipose TRX2 deficiency activates mtDNA-NLRP3 to impair thermogenesis and protect against diet-induced insulin resistance
Yanrui Huang, Huanjiao Jenny Zhou, Haifeng Zhang, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 9
Open Access | Times Cited: 37
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Baihui Zhang, Fan Yin, Yanan Qiao, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 35
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Algera Goga, Markus Stoffel
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 417-439
Closed Access | Times Cited: 34
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
Henry N. Ginsberg, Neil Hounslow, Yusuke Senko, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 898-908
Open Access | Times Cited: 31
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Ewa Karwatowska‐Prokopczuk, Jean‐Claude Tardif, Daniel Gaudet, et al.
Journal of clinical lipidology (2022) Vol. 16, Iss. 5, pp. 617-625
Open Access | Times Cited: 31

Scroll to top